Navigation Links
Clarus Ventures Closes $660 Million Fund
Date:2/25/2008

th leadership experience in major biotechnology and pharmaceutical companies.

About Clarus Ventures

Founded by a group of accomplished investment professionals with extensive and complementary industry backgrounds, Clarus Ventures is a life sciences venture capital firm with a team that has a long history of success in creating value. Internal operating experience combined with longstanding relationships with key opinion leaders and industry thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus Ventures augments its core expertise of investing in biopharmaceuticals and medical technology with deep and diverse expertise in research and development, commercialization, business development and operations management at the global level. The firm has $1.2 billion under management and has offices in Cambridge, Mass., and South San Francisco, CA.

For additional information on Clarus Ventures, please visit http://www.clarusventures.com.

CONTACTS:

Nicholas Galakatos, Ph.D., Clarus Ventures, Tel.: 617-949-2223

Robert Liptak, Clarus Ventures, Tel.: 617-694-2222

Tony Russo, Russo Partners, Tel.: 212-845-4251


'/>"/>
SOURCE Clarus Ventures, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
2. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
3. Khosla Ventures and BIOeCON Form KiOR Inc.
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
6. Dan Broderick Joins Prolog Ventures as Partner
7. Hank Plain Joins Morgenthaler Ventures as Partner
8. Ocera Therapeutics Closes $35.5 Million Series C Financing
9. Sinovac Closes $9.75 Million Private Placement
10. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
11. Progentix Orthobiology B.V. Closes Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Editors note: This is the first of a series of columns ... and advice on IT leadership and the challenges they face. ... 95 percent of his customers want more of what he has ... ready to meet that demand. , ,David Wallace is the CIO ...
... arteries. Source: National Institutes of Health. Madison, Wis. ... researcher, announced on Wednesday that it will receive a $1.26 ... National Institutes of Health. , ,The funds will be used ... anemia, a blood disorder that kills red blood cells. This ...
... getting a flu shot this season and you want to fix ... mirror. If the face you see belongs to someone who buys ... the problem. , ,The looming shortage of flu vaccine comes down ... in the business of making vaccines. Why? The capital costs are ...
Cached Biology Technology:MATC faces demand for less paper and more integration 2MATC faces demand for less paper and more integration 3Mirus receives $1.26 million SBIR grant to combat anemia 2Want to squeeze U.S. pharmaceutical companies? Be careful what you ask for 2Want to squeeze U.S. pharmaceutical companies? Be careful what you ask for 3
(Date:7/9/2014)... of the amphibians with the highest distribution in the ... water where it comes into contact with the red ... out by the Spaniard Germn Orizaola from the University ... frogs have developed a defensive response to the invasive ... if they co-exist with the crayfish. , Numerous invasive ...
(Date:7/9/2014)... laboratory testing, countless measurement results accrue. To completely ... extremely time consuming. In fact, researchers in the ... managing data, according to an online survey of ... the Fraunhofer Institute for Applied Information Technology FIT ... that they have no centralized or structured approach ...
(Date:7/9/2014)... inhibitors and N-methyl-D-aspartate receptor antagonists can alleviate ... to affect irreversible cognitive dysfunction and effectively ... Amyloid beta peptide (Aβ) vaccines reduced and ... (AD) transgenic mouse model, and significantly improved ... and his team, First Affiliated Hospital of ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3Managing the data jungle 2Managing the data jungle 3
... researchers have sequenced the genomes of two bacteria that ... Brazil and elsewhere. , The researchers are now analysing ... that could be used to develop vaccines and diagnostic ... in pigs and costs the Brazilian pig-breeding industry US$200 ...
... once were bountiful in an area near the town of ... grew more plentiful, browsing heavily on young willows. Today, there ... warblers in what is now a grassland meadow. These profound ... top predator. That's the compelling finding of the paper, "Human ...
... of boosting the yield of a major crop by stopping ... is the most important oilseed crop in India after groundnut. ... seeds. However, because the seedpods open naturally to disperse their ... , This 'pod shatter' also makes it difficult for farmers ...
Cached Biology News:Wolves' top-down effect 2
...
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: